These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30579151)

  • 1. Assessment and determinants of whole blood and plasma fibrinolysis in patients with mild bleeding symptoms.
    Vries MJA; Macrae F; Nelemans PJ; Kuiper GJAJM; Wetzels RJH; Bowman P; Verhezen PWM; Ten Cate H; Ariëns RAS; Henskens YMC
    Thromb Res; 2019 Feb; 174():88-94. PubMed ID: 30579151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
    Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
    J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis.
    Scarlatescu E; Kim PY; Marchenko SP; Tomescu DR
    J Thromb Haemost; 2024 Apr; 22(4):1223-1235. PubMed ID: 38104723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause.
    Gebhart J; Kepa S; Hofer S; Koder S; Kaider A; Wolberg AS; Haslacher H; Quehenberger P; Eigenbauer E; Panzer S; Mannhalter C; Pabinger I
    Ann Hematol; 2017 Mar; 96(3):489-495. PubMed ID: 28018998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.
    Kuiper GJ; Kleinegris MC; van Oerle R; Spronk HM; Lancé MD; Ten Cate H; Henskens YM
    Thromb J; 2016; 14():1. PubMed ID: 26770073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonactivated thromboelastometry able to detect fibrinolysis in contrast to activated methods (EXTEM, INTEM) in a bleeding patient.
    Durila M
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):828-830. PubMed ID: 26656899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of fibrinolytic activity in pregnant patients exposed to tissue plasminogen activator: an in vitro study utilizing rotational thromboelastometry.
    Tran A; Katz D
    Int J Obstet Anesth; 2024 Aug; 59():103994. PubMed ID: 38632015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased resistance to tissue plasminogen activator-induced fibrinolysis in healthy subjects from Thailand.
    White NJ; Taflin N; Lim EB; Akaraborworn O
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):356-360. PubMed ID: 29337700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global assays of fibrinolysis.
    Ilich A; Bokarev I; Key NS
    Int J Lab Hematol; 2017 Oct; 39(5):441-447. PubMed ID: 28497494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of results obtained using clot-fibrinolysis waveform analysis and global fibrinolysis capacity assay with rotational thromboelastography.
    Tsuchida T; Hayakawa M; Kumano O
    Sci Rep; 2024 Mar; 14(1):7602. PubMed ID: 38556522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal Transitions in Fibrinolysis after Trauma: Adverse Outcome Is Principally Related to Late Hypofibrinolysis.
    Rossetto A; Vulliamy P; Lee KM; Brohi K; Davenport R
    Anesthesiology; 2022 Jan; 136(1):148-161. PubMed ID: 34724559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis.
    Gitto S; Romanelli RG; Cellai AP; Lami D; Vizzutti F; Abbate R; Margheri F; Fibbi G; Del Rosso M; Laffi G
    Intern Emerg Med; 2021 Mar; 16(2):339-347. PubMed ID: 32445164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.
    Siudut J; Iwaniec T; Plens K; Pieters M; Undas A
    Thromb Res; 2021 Jan; 197():1-7. PubMed ID: 33157491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
    Dirkmann D; Radü-Berlemann J; Görlinger K; Peters J
    J Trauma Acute Care Surg; 2013 Feb; 74(2):482-8. PubMed ID: 23354242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of coagulation and fibrinolysis in Irish Wolfhounds and age-matched control dogs using tissue plasminogen activator-augmented viscoelastic testing.
    Davis S; Fletcher DJ; Newman A; Brooks MB
    J Vet Emerg Crit Care (San Antonio); 2024; 34(3):222-230. PubMed ID: 38775137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study.
    Veen CSB; Huisman EJ; Cnossen MH; Kom-Gortat R; Rijken DC; Leebeek FWG; de Maat MPM; Kruip MJHA
    Haemophilia; 2020 May; 26(3):e106-e115. PubMed ID: 32337845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.